PT - JOURNAL ARTICLE AU - Meulenbeld, Amber AU - Ramondt, Steven AU - Sweegers, Maike G. AU - Quee, Franke A. AU - Prinsze, Femmeke J. AU - Hoogendijk, Emiel O. AU - Swinkels, Dorine W. AU - van den Hurk, Katja TI - Effectiveness of Ferritin-guided Donation Intervals in Blood Donors: results of the Stepped Wedge Cluster-randomised FIND’EM Trial AID - 10.1101/2023.01.24.23284933 DP - 2023 Jan 01 TA - medRxiv PG - 2023.01.24.23284933 4099 - http://medrxiv.org/content/early/2023/01/25/2023.01.24.23284933.short 4100 - http://medrxiv.org/content/early/2023/01/25/2023.01.24.23284933.full AB - Importance Blood donors are at increased risk for iron deficiency. Current hemoglobin (Hb) monitoring policies are inadequate and new iron management strategies are warranted.Objective To determine the effects of ferritin-guided donation intervals for whole blood donors on Hb and ferritin levels, Hb deferral, iron deficiency (ferritin < 15 ng/mL) prevalence, donor return, and iron deficiency-related symptoms.Design Between November 2017 and November 2019 a ferritin-guided donation interval policy was gradually implemented nationwide and evaluated through a stepped-wedge cluster-randomized controlled trial.Setting All blood collection centers in the Netherlands.Participants 412,888 whole blood donors were included.Interventions Ferritin was measured in all new donors and at every 5th whole blood donation. Subsequent donation intervals were extended to six months if ferritin is 15 ≤ 30 ng/mL and to twelve months if ferritin is <15 ng/mL (iron deficient).Main outcomes and Measures The primary outcomes are ferritin and Hb levels, iron deficiency, Hb deferral, and donor return. Secondary outcomes are self-reported iron deficiency-related symptoms.Results We measured 36,099 donors, median age 43 years and 52% female, making 37,621 donations during the study period. Ferritin-guided donation intervals increased log-transformed ferritin levels at all time points in the trial, up to 0.56 log-transformed ng/mL as compared to baseline (95% CI 0.49 – 0.63, p <0.001). Hb increased as well, up to 0.39 g/dL (95% CI 0.32 – 0.45, p <0.001). Decreased odds of 13% (95% CI 8 – 22, p <0.001) for iron deficiency and 20% (95% CI 6 – 47, p <0.001) for Hb deferral were reported compared to baseline. Odds of donor return decreased over the course of the trial, as low as 56% (95% CI 48 – 66, p <0.001). We found no evidence for improved self-reported iron deficiency-related symptoms after implementation of the new policy.Conclusion and Relevance Ferritin-guided donation intervals significantly increased overall Hb and ferritin levels, thereby decreasing the prevalence of iron deficiency and Hb deferrals in whole blood donors. Ferritin-guided donation intervals seem beneficial for Hb levels and iron maintenance, but additional efforts are required to retain donors and to remedy self-reported iron deficiency-related symptoms.Trial Registration This trial has been registered in the Dutch trial registry (NTR6738) on September 29th,, 2017 (https://trialsearch.who.int/Trial2.aspx?TrialID=NTR6738).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNTR6738Clinical Protocols https://pubmed.ncbi.nlm.nih.gov/32998766/ Funding StatementThe current project is supported by the Product and Process Development Cellular Products Grant (PPOC18-15) granted to K. van den Hurk by the Research Programming Committee, Sanquin, Amsterdam, The Netherlands.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Board of Directors, the Medical Advisory Council and Ethics Advisory Council of Sanquin Blood Supply Foundation gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.